Jun Yin, PhD

Research Scientist

T 414-219-4529
F 414-219-5381

Aurora Research Institute
960 N. 12th Street, Suite 4120
Milwaukee, WI 53233

Research Scientist Jun Yin, PhD

Learn About Our Research

Find out more about our current research projects.


Dr. Yin’s research focus is determining gene signatures that will serve as biomarkers to assist clinicians in accurately predicting drug resistance, particularly in patients with breast cancer who test positive for human epidermal growth factor receptor 2 (HER2). As this receptor renders some breast cancer treatments ineffective, this research may help clinicians prescribe more effective treatments.
Educated as a pharmaceutical and chemical engineer and statistician, and possessing a background in cancer biology from her time at MD Anderson Cancer Center in Houston, Dr. Yin has gained extensive experience working with poly ADP-ribose polymerase (PARP) inhibitors and their synergistic effect in women’s cancers. PARP inhibitors, some of which have been widely tested in clinical trials and are approved by the Food and Drug Administration, target certain types of cancer cells, causing them to die.
Since joining Aurora Research Institute, Dr. Yin is extending her holistic, systems biology approach, integrating computational and experimental techniques in the institute’s Discovery Laboratory, to conduct her research into breast cancer biomarkers. She is also examining the underlying mechanisms that give these biomarkers their predictive power with the goal of revealing promising new therapies, such as novel immunotherapy strategies, for drug-resistant HER2-postive breast cancer patients.


Doctorate, Chemical Engineering, Minor in Statistics
University of Florida, Gainesville

Bachelor of Science, Pharmaceutical Engineering
Xi’an University of Technology, China

Professional highlights

First Place Judged Poster, Aurora Scientific Day, 2018
Aurora Research Institute Seed Grant Award, 2018
Postdoctoral fellowship, Computational Cancer Biology Training Program, Cancer Prevention Research Institute of Texas, 2017-2018
Postdoctoral fellowship, MD Anderson Cancer Center, 2015-2017
Best Poster Presentation, Pruitt Research Day, University of Florida, 2014
Achievement Award for Engineers, University of Florida, 2009


Sand A, Piacsek M, Donohoe DL, Duffin AT, Riddell GT, Sun C, Tang M, Rovin RA, Tjoe JA, Yin J. WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer. Cancer Lett. 2020;472:119-131.

Sand A, Duffin A, Riddell GT, Piacsek M, Last B, Sun C, Richard RA, Tjoe JA, Yin J. Immunotherapy implication of signature-guided biomarker discovery for trastuzumab-resistant HER2-positive breast cancer. MedRxiv. 2020; doi: https://doi.org/10.1101/2020.01.17.20017947.

Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB. BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency. Cancer Cell. 2018;33:401-416.e8.

McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Lam TNA, Li Y, Sun C, Li Y, Schmandt R, Wu JY, Hu L, Liang Y, Peng G, Jonasch E, Menter D, Yates MS, Kopetz S, Lu KH, Broaddus R, Mills GB, Sahni N, Lin SY. Proteome instability is a therapeutic vulnerability in mismatch repair-deficient cancer. Cancer Cell. 2020;37:371-386.e12.

Collaborate on Research 

Collaborate with Aurora on medical research or product development.

Become a Research Sponsor

You can sponsor original research or clinical trials.

Work for Aurora

Learn more about our employment opportunities.

Make a Donation

Your donation can help fund critical research or help to develop new medical products.